Navigation Links
Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
Date:6/12/2008

or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on April 15, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors) Janine McCargo (media)

(646) 536-7002 (646) 536-7033

sephraim@theruthgroup.com jmcc
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Selexis SA, a serial innovation company with proven ... for drug discovery to commercial manufacturing, announced today all ... Sequencing (NGS) data packages. The NGS analysis of ... the integrity of the gene, validation of the left ...
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... ... addition to the traditional pin connection, Tekscan is now offering a lower-cost termination method to ... , ... 30, 2010 -- Tekscan, Inc. announces a new lower-cost connection option for its custom ...
... ... the effect of HGH on athletes and other users sports performance , ... Copenhagen, Denmark (PRWEB) June 30, 2010 -- ... improve a sportsman’s physical performance., , ,However, few researchers from Denmark revealed that the level ...
... taken the first steps toward reducing the size and ... frequency spectrum. By combining a detector and laser ... the researchers rendered unnecessary the precision alignment of optical ... detector. The new solid-state system puts to use ...
Cached Biology Technology:Lower-Cost ZIF and LIF-Compatible Connection Option for Tekscan Custom Force Sensors 2Recent Study Reports Reveals that HGH May Aid Performance 2Sandia Labs reports first monolithic terahertz solid-state transceiver 2
(Date:12/17/2014)... and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced ... 2015-2019" report to their offering. ... upcoming in this market is the increasing demand for ... recording of patient data for quick and correct diagnosis ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... SecurePad with Fingerprint Sensor Recognized in the ... Enabling Technologies Product Category, ... SYNA ), a leading developer of human interface ... that,its SecurePad(TM) solution has been selected as a CES ...
... Cranberry sauce is not the star of the traditional ... benefits, the lowly condiment takes center stage. In fact, ... compounds in cranberries are able to alter E. coli ... illnesses (from kidney infections to gastroenteritis to tooth decay), ...
... A major study that will provide a new window ... by the La Jolla Institute for Allergy & Immunology ... five-year study, funded by the National Institute of Allergy ... of Health, could lead to revolutionary new approaches for ...
Cached Biology News:Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree 2Synaptics SecurePad(TM) Selected as CES Innovations 2008 Design and Engineering Award Honoree 3Cranberry sauce: good for what ails you 2Cranberry sauce: good for what ails you 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 2NIH selects LIAI for major study on allergy molecular causes and possible treatments 3NIH selects LIAI for major study on allergy molecular causes and possible treatments 4
...
... solution has effect on enhancing an antigen-antibody ... than the one obtained by conventional methods. ... antibody used and exposure time in fluorescence/luminescence ... with high S/N ratio and low background. ...
... this enzyme exists predominantly as XDH which ... a critical plasma antioxidant. During ischemia, ... radical producing XO by oxidation of essential ... cleavage of the amino-terminus. AO has ...
... 2 bridges the gap between the 500 ... device combines the speed of the classic ... membrane area for superior recoveries from very ... of PES, Cellulose Triacetate membranes, Vivaspin 2 ...
Biology Products: